Researcher Profile

Researcher Profile

Monika Joshi, MD, MRCP

Monika Joshi, MD, MRCP

Associate Professor, Department of Medicine
Division of Hematology and Oncology
Assistant Professor, Department of Medicine
Scientific Program:Next-Generation Therapies
Disease Teams:
Genitourinary Cancer

Research Interests

Dr. Monika Joshi’s research focus is in the field of genitourinary tumors, particularly in the field of immunotherapy and targeted therapy.

  • Neoplasms
  • Therapeutics
  • Carcinoma
  • Survival
  • Non-Small Cell Lung Carcinoma
  • Immunotherapy
  • Prostatic Neoplasms
  • Renal Cell Carcinoma
  • Urinary Bladder Neoplasms
  • Smoking
  • Drug Therapy
  • Smokers

Clinical Trials

A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283 (Cetrelimab), an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Locally Advanced Urothelial Cancer with Selected FGFR Gene Alterations
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With or Without Atezoluzumab in Localized Muscle Invasive Bladder Cancer
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 Study of Bladder-SparIng ChemoradiatioN with CIPosItive bladdeR cancEr (INSPIRE)EA8185
Computer-Aided Diagnosis of Cancer in Urinary Tract on Multi-Detector Row CT Urography
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Renal Cell Cancer (PDIGREE)
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Follow up for patients on Phase lb Clinical Trial of Eribulin Mesylate and the PD-Ll Monoclonal Antibody, Avelumab, in Cisplatin Ineligible or Platinum Resistant Metastatic Urothelial Cell Cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
Observational Study to Determine the Differences in Molecular Characterization between Smokers vs. Non-smokers in Patients with Stage IV Bladder Cancer and their Correlation with Clinical Outcome
Tissue and Blood Collection from Patients with Suspected Lung Cancer

Recent Publications


Joshi, M, Holder, SL, Zhu, J, Zheng, H, Komanduri, S, Warrick, J, Yasin, H, Gajre, R, Jia, B, Drabick, J, Degraff, D & Zakharia, Y 2021, 'Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study', European Urology Focus.
Nesterova, D, Zhu, J, Kramer, C, Vasekar, M, Truica, C, Joshi, A, Hayes, M, Kessler, J, Saunders, EFH, Drabick, J & Joshi, M 2021, 'Group-led creative writing and behavioural health in cancer: a randomised clinical trial', BMJ Supportive and Palliative Care.
Esagian, SM, Khaki, AR, Diamantopoulos, LN, Carril-Ajuria, L, Castellano, D, De Kouchkovsky, I, Park, JJ, Alva, A, Bilen, MA, Stewart, TF, McKay, RR, Santos, VS, Agarwal, N, Jain, J, Zakharia, Y, Morales-Barrera, R, Devitt, ME, Nelson, A, Hoimes, CJ, Shreck, E, Gartrell, BA, Sankin, A, Tripathi, A, Zakopoulou, R, Bamias, A, Rodriguez-Vida, A, Drakaki, A, Liu, S, Kumar, V, Lythgoe, MP, Pinato, DJ, Murgic, J, Fröbe, A, Joshi, M, Isaacsson Velho, P, Hahn, N, Alonso Buznego, L, Duran, I, Moses, M, Barata, P, Galsky, MD, Sonpavde, G, Yu, EY, Msaouel, P, Koshkin, VS & Grivas, P 2021, 'Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes', BJU International.


The COVID-19 and Cancer Consortium 2020, 'A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance', Cancer Cell, vol. 38, no. 6, pp. 761-766.
Joshi, M, Grivas, P, Mortazavi, A, Monk, P, Clinton, SK, Sue-Ann Woo, M, Holder, SL, Drabick, JJ & Yin, M 2020, 'Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer', Cancer medicine, vol. 9, no. 24, pp. 9365-9372.
COVID-19 and Cancer Consortium 2020, 'Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study', The Lancet, vol. 395, no. 10241, pp. 1907-1918.
Necchi, A, Madison, R, Pal, SK, Ross, JS, Agarwal, N, Sonpavde, G, Joshi, M, Yin, M, Miller, VA, Grivas, P, Chung, JH & Ali, SM 2020, 'Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma', European Urology Focus.
Miller, NJ, Khaki, AR, Diamantopoulos, LN, Bilen, MA, Santos, V, Agarwal, N, Morales-Barrera, R, Devitt, M, Nelson, A, Hoimes, CJ, Shreck, E, Assi, H, Gartrell, BA, Sankin, A, Rodriguez-Vida, A, Lythgoe, M, Pinato, DJ, Drakaki, A, Joshi, M, Isaacsson Velho, P, Hahn, N, Liu, S, Alonso Buznego, L, Duran, I, Moses, M, Jain, J, Murgic, J, Barata, P, Tripathi, A, Zakharia, Y, Galsky, MD, Sonpavde, G, Yu, EY, Lyman, GH & Grivas, P 2020, 'Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study', The Journal of Urology, vol. 204, no. 1, pp. 63-70.
Khaki, AR, Li, A, Diamantopoulos, LN, Bilen, MA, Santos, V, Esther, J, Morales-Barrera, R, Devitt, M, Nelson, A, Hoimes, CJ, Shreck, E, Assi, H, Gartrell, BA, Sankin, A, Rodriguez-Vida, A, Lythgoe, M, Pinato, DJ, Drakaki, A, Joshi, M, Isaacsson Velho, P, Hahn, N, Liu, S, Alonso Buznego, L, Duran, I, Moses, M, Jain, J, Murgic, J, Baratam, P, Barata, P, Tripathi, A, Zakharia, Y, Galsky, MD, Sonpavde, G, Yu, EY, Shankaran, V, Lyman, GH & Grivas, P 2020, 'Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors', Cancer, vol. 126, no. 6, pp. 1208-1216.
Dudek, AZ, Liu, LC, Gupta, S, Logan, TF, Singer, EA, Joshi, M, Zakharia, YN, Lang, JM, Schwarz, JK, Al-Janadi, A & Alva, AS 2020, 'Phase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003', Journal of Clinical Oncology, vol. 38, no. 11, pp. 1138-1145.
Yin, M, Grivas, P, Wang, QE, Mortazavi, A, Emamekhoo, H, Holder, SL, Drabick, JJ, Woo, MSA, Pal, S, Vasekar, M, Folefac, E, Clinton, SK, Monk, P & Joshi, M 2020, 'Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer', Oncologist, vol. 25, no. 8, pp. 680-688.


Voss, MH, Bhatt, RS, Vogelzang, NJ, Fishman, M, Alter, RS, Rini, BI, Beck, JT, Joshi, M, Hauke, R, Atkins, MB, Burgess, E, Logan, TF, Shaffer, D, Parikh, R, Moazzam, N, Zhang, X, Glasser, C, Sherman, ML & Plimack, ER 2019, 'A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma', Cancer, vol. 125, no. 14, pp. 2400-2408.
Joshi, A, Hillwig-Garcia, J, Joshi, M, Lehman, E, Khan, A, Llorente, A & Haidet, P 2019, 'Comics as an Educational Tool on a Clinical Clerkship', Academic Psychiatry, vol. 43, no. 3, pp. 290-293.
Yin, M, Zhao, J, Monk, P, Martin, D, Folefac, E, Joshi, M, Jin, N, Mortazavi, A, Verschraegen, C & Clinton, S 2020, 'Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancer', Cancer medicine, vol. 9, no. 1, pp. 27-34.
Zhu, J, Hussain, M, Joshi, A, Truica, CI, Nesterova, D, Collins, J, Saunders, EFH, Hayes, M, Drabick, JJ & Joshi, M 2020, 'Effect of creative writing on mood in patients with cancer', BMJ Supportive and Palliative Care, vol. 10, no. 1, pp. 64-67.
Loriot, Y, Necchi, A, Park, SH, Garcia-Donas, J, Huddart, R, Burgess, E, Fleming, M, Rezazadeh, A, Mellado, B, Varlamov, S, Joshi, M, Duran, I, Tagawa, ST, Zakharia, Y, Zhong, B, Stuyckens, K, Santiago-Walker, A, De Porre, P, O'Hagan, A, Avadhani, A & Siefker-Radtke, AO 2019, 'Erdafitinib in locally advanced or metastatic urothelial carcinoma', New England Journal of Medicine, vol. 381, no. 4, pp. 338-348.
Zaleski, M, Gogoj, A, Walter, V, Raman, JD, Kaag, M, Merrill, SB, Drabick, J, Joshi, M, Holder, S, DeGraff, DJ & Warrick, JI 2019, 'Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system', Human Pathology, vol. 84, pp. 275-282.
Joshi, M, Warrick, JI, Yin, M, Holder, SL & Drabick, JJ 2019, 'Need for a personalized approach for muscle invasive bladder cancer: Role of tumor biology in response to neoadjuvant chemotherapy', Translational Andrology and Urology, vol. 8, pp. S99-S103.


Yin, M, Grivas, P, Emamekhoo, H, Mendiratta, P, Ali, S, Hsu, JA, Vasekar, M, Drabick, JJ, Pal, S & Joshi, M 2018, 'ATM/RB1 mutations predict shorter overall survival in urothelial cancer', Oncotarget, vol. 9, no. 24, pp. 16891-16898.


Venur, VA, Joshi, M, Nepple, KG & Zakharia, Y 2017, 'Spotlight on nivolumab in the treatment of renal cell carcinoma: Design, development, and place in therapy', Drug Design, Development and Therapy, vol. 11, pp. 1175-1182.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)